Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya
--, --
Finerenone is a Novel selective Non-steroidal Mineralocorticoids Receptor Antagonist. Finerenone is indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.
Keywords: Finerenone, Chronic kidney disease, Solubility, BCS Class.
Journal Name :
EPRA International Journal of Research & Development (IJRD)

Published on : 2023-02-25

Vol : 8
Issue : 2
Month : February
Year : 2023
Copyright © 2023 EPRA JOURNALS. All rights reserved
Developed by Peace Soft